Literature DB >> 2883213

Treatment of Barrett's esophagus with H2 blockers.

B T Cooper, G O Barbezat.   

Abstract

The effect of the H2 receptor antagonists, cimetidine and ranitidine, on Barrett's esophagus was assessed in a retrospective study. There was no evidence of regression of Barrett's epithelium in the 22 patients treated for a mean of 13 months with 800-1,600 mg/day cimetidine, or in the 13 patients treated for a mean of 5.7 months with 300 mg/day ranitidine. Eight of 12 esophageal (Barrett's) ulcers healed on cimetidine therapy over a mean period of 8.7 months, and eight of nine esophageal ulcers healed on ranitidine therapy over a mean period of 3.5 months. We conclude that short-term treatment with H2 blockade does not cause regression of Barrett's esophagus, although such treatment can heal esophageal ulcers.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2883213     DOI: 10.1097/00004836-198704000-00006

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  4 in total

1.  Regression of Barrett's esophagus by laser ablation in an anacid environment.

Authors:  R E Sampliner; L J Hixson; M B Fennerty; H S Garewal
Journal:  Dig Dis Sci       Date:  1993-02       Impact factor: 3.199

2.  Correlation between basal acid output and daily ranitidine dose required for therapy in Barrett's esophagus.

Authors:  M J Collen; D A Johnson
Journal:  Dig Dis Sci       Date:  1992-04       Impact factor: 3.199

3.  Lack of impact of therapy on extent of Barrett's esophagus in 67 patients.

Authors:  R E Sampliner; H S Garewal; M B Fennerty; M Aickin
Journal:  Dig Dis Sci       Date:  1990-01       Impact factor: 3.199

4.  Optimal management of Barrett's esophagus: pharmacologic, endoscopic, and surgical interventions.

Authors:  Vani Ja Konda; Kunal Dalal
Journal:  Ther Clin Risk Manag       Date:  2011-11-22       Impact factor: 2.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.